Role of dynamic mri and clinical assessment in predicting histologic response to neoadjuvant chemotherapy in bone sarcomas

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 37, Issue 4, 2014, Pages 384-390

  Amit, Priyadarshi ^a   Patro, Dilip K ^b   Basu, Debdatta ^b   Elangovan, Sundar ^b   Parathasarathy, Vadasoundaram ^b  

^a Acharya Bhikshu Government Hospital   (India)

^b JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Dynamic MRI; Malignant fibrous histiocytoma; Neoadjuvant chemotherapy; Osteosarcoma

Indexed keywords

ADOLESCENT; ADULT; BODY TEMPERATURE; BONE NEOPLASMS; CHILD; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEOADJUVANT THERAPY; OSTEOSARCOMA; PAIN; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84905102607     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31827b4f6f     Document Type: Article

References (23)

1. Raymond AK, Chawla SP, Carrasco CH, et al. Osteosarcoma chemotherapy effect: a prognostic factor. Semin Diagn Pathol. 1987; 4: 212-236.
2. Rosen G, Caparros B, Huvos A, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982; 49: 1221-1230.
3. Kawai A, Sugihara S, Kunisada T, et al. Imaging assessment of the response of bone tumors to preoperative chemotherapy. Clin Orthop Relat Res. 1997; 337: 216-225.
4. Wunder JS, Paulian G, Huvos A, et al. The histological response to chemotherapy as a predictor of the oncologic outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg. 1998; 80-A: 1020-1033.
5. Huvos AG, Rosen G, Marcove RC, et al. Primary osteogenic sarcoma: pathologic aspect in 20 patients after treatment with chemotherapy-"en bloc" resection and prosthetic bone replacement. Arch Pathol Lab Med. 1977; 101: 14-18.
6. Gherlinzoni F, Picci P, Bacci G, et al. Limb sparing versus amputation in osteosarcoma: correlation between local control, surgical margins and tumor necrosis: Instituto Rizzoli experience. Ann Oncol. 1992; 3: S23-S27.
7. Picci P, Rougraff BT, Bacci G, et al. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol. 1993; 11: 1763-1769.
8. Dyke JP, Panicek DM, Healey JH, et al. Osteogenic and Ewing sarcoma: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology. 2003; 228: 271-278.
9. Fletcher BD, Hanna SL, Fairclough DL, et al. Pediatric musculoskeletal tumors: use of dynamic, contrast-enhanced MR imaging to monitor response to chemotherapy. Radiology. 1992; 184: 243-248.
10. Smith J, Heelan RT, Huvos AG, et al. Radiographic changes in primary osteogenic sarcoma following chemotherapy. Radiology. 1982; 143: 355-360.
11. Carrasco HC, Charnsangavej C, Raymond MK, et al. Osteosarcoma: angiographic assessment of response to preoperative chemotherapy. Radiology. 1989; 170: 839-842.
12. Welling RM, Davies AM, Pynsent PB, et al. The value of computed tomographic measurements in osteosarcoma as a predictor of response to adjuvant chemotherapy. Clin Radiol. 1994; 49: 19-23.
13. Holscher HC, Bloem JL, Nooy MA, et al. The value of MR imaging in monitoring the effect of chemotherapy on bone sarcomas. AJR. 1990; 154: 763-769.
14. Cheon GJ, Kim MS, Lee JA, et al. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI. J Nucl Med. 2009; 50: 1435-1440.
15. Taki J, Inaki A, Wakabayashi H, et al. Early prediction of histopathological tumor response to preoperative chemotherapy by Tc-99m MIBI imaging in bone and soft tissue sarcomas. Clin Nucl Med. 2010; 35: 154-159.
16. Jurgens H, Exner U, Gadner H, et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. Cancer. 1988; 61: 23-32.
17. Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma result of a randomized cooperative trial (COSS 82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988; 6: 329-337.
18. Moertel CG, Hanley JA. The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer. 1976; 38: 388-394.
19. Uhl M, Saueressig U, Buiren MV, et al. Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion and perfusion weighted magnetic resonance imaging. Invest Radiol. 2006; 41: 618-623.
20. Erlemann R, Sciuk J, Bosse A, et al. Response of osteosarcoma and Ewing sarcoma to preoperative chemotherapy: assessment with dynamic and static MR imaging and skeletal scintigraphy. Radiology. 1990; 175: 791-796.
21. Hendershot E, Pappo A, Malkin D, et al. Tumor necrosis in pediatric osteosarcoma: impact of modern therapies. J Pediatr Oncol Nurs. 2006; 23: 176-181.
22. Shin KH, Moon SH, Suh JS, et al. Tumor volume change as a predictor of chemotherapeutic response in osteosarcoma. Clin Orthop Relat Res. 2000; 376: 200-208.
23. Van der Woude HJ, Bloem JL, Verstraete KL, et al. Osteosarcoma and Ewing's sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor before surgery. AJR. 1995; 165: 593-598.